Phase III Studies of Pharmaceutical Agents in the Treatment of Postmenopausal Osteoporosis.
Link to PubMed (Opens new window. Close the PubMed window to return to this page.)
Women with postmenopausal osteoporosis, with and without fractures, are being followed in placebo controlled double blind multicenter protocols. The primary parameters of efficacy are bone density and incidence of new fractures. The agents currently being tested are the selective estrogen receptor modulator, raloxifene, and the bisphosphonate, alendronate. The current emphasis with raloxifene is to determine possible long term adverse actions. Alendronate is being administered intermittently to determine if this dosing regimen, which should be more acceptable to patients, is as effective as daily dosing in the prevention and treatment of osteoporosis.
Moses, A.M., Thomas, D.G., Canfield, M.C., Collins, G.H.: Central diabetes insipidus due to cytomegalovirus infection of the hypothalamus in a patient with AIDS: A clinical, pathological and immunohistochemical case study. J. Clin. Endocrinol. Metab. 88: 51-54, 2003.
Kelly, J.J., Moses, A.M: Osteoporosis in men: the role of testosterone and other sex-related factors. Curr Opin Endocrinol and Diabetes 12:452-458, 2005.
Weinstock, M.A., Moses, A.M. Skin cancer meets vitamin D: The way forward for dermatology and public health. J. Am. Acad. Dermatol. 61: 720-724,2009.